WuXi XDC Cayman Inc. (HKG:2268)

Market Cap	92.21B
Revenue (ttm)	5.58B
Net Income (ttm)	1.45B
Shares Out	1.23B
EPS (ttm)	1.12
PE Ratio	67.15
Forward PE	45.67
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,688,708
Average Volume	6,123,432
Open	75.50
Previous Close	74.50
Day's Range	73.25 - 75.70
52-Week Range	20.70 - 78.55
Beta	n/a
RSI	66.40
Earnings Date	Nov 18, 2025

About WuXi XDC Cayman

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. The company was founded in 2013 and is headquartered in Wuxi, China....

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2013
• Employees: 2,041
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2268

Financial Performance

In 2024, WuXi XDC Cayman's revenue was 4.05 billion, an increase of 90.80% compared to the previous year's 2.12 billion. Earnings were 1.07 billion, an increase of 277.24%.

Financial numbers in CNY